Latest Novartis Kisqali® NATALEE analysis reinforces 25% reduction in risk of recurrence across broad population of patients with early breast cancer; supports regulatory submissions ...Middle East

With 5.6 months of additional follow-up and 78.3% of patients having completed Kisqali® (ribociclib) investigational treatment, the updated analysis shows sustained iDFS benefit and stability in secondary endpoints including overall survival (OS)1,2 iDFS benefit remains consistent across...

Hence then, the article about latest novartis kisqali natalee analysis reinforces 25 reduction in risk of recurrence across broad population of patients with early breast cancer supports regulatory submissions was published today ( Friday 08/12/2023 - 05:24 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Latest Novartis Kisqali® NATALEE analysis reinforces 25% reduction in risk of recurrence across broad population of patients with early breast cancer; supports regulatory submissions )

Also on site :

• Meta Prepares 8,000 Layoffs to Offset AI Infrastructure Investments .. PYMNTS.com
• China’s DeepSeek unveils latest model a year after upending global tech
• Ella Langley Is Hosting 'Dinner at the Opry' — Here's How You Can Grab a Seat